Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: bempedoic acid | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 7 Parkinson's papers of 902 | 0.73 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 11356
Sealed predictions
- ACLY in dopamine neurons, braak-0.39 (p 0.293) → -0.45 (p 0.230)receipt 11362
Swarm cases
receipt 11362: ACLY in dopamine neurons, braak
- power
- full sample -0.20 (p 0.424, n 18), 95% CI -0.61 to +0.29. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.22 (p 0.374, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.18 (p 0.476, n 18). could be the mix.
- skeptic
- leave-one-out range -0.35 to -0.09, sign flips 0; without severely affected donors -0.20 (p 0.424, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ACLY in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts